CD8A and neoplasm: The anti-CCR4 antibody, mogamulizumab, has demonstrated an effective reduction in the frequency of effector Tregs that selectively augment the induction of tumor antigen-specific CD4 + and CD8 + T cells in vivo [36, 37].